Search research articles
Contact Us
Filters
Showing results (51-60 of 225) with videos related to
Page
of 23
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 1989
What is the choice of treatment for hairy cell leukemia?
H M Golomb, M J Ratain, J Moormeier
Cancer Research
|
August 1, 1986
Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum(II) in patients with advanced cancer
R L Schilsky, K O'Laughlin, M J Ratain
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 1, 1995
Pushing the envelope: informed consent in phase I trials
C K Daugherty, M J Ratain, M Siegler
Clinical Pharmacology and Therapeutics
|
July 23, 2013
CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality
M J Ratain, Y Nakamura, N J Cox
Cancer Surveys
|
January 1, 1993
Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring
K Kobayashi, D I Jodrell, M J Ratain
Blood
|
June 15, 1990
Duration of response after interferon treatment of hairy cell leukemia
R Mick, M J Ratain, H M Golomb
Clinical Pharmacology and Therapeutics
|
January 13, 2016
The Outlier in All of Us: Why Implementing Pharmacogenomics Could Matter for Everyone
P H O'Donnell, K Danahey, M J Ratain
Clinical Pharmacology and Therapeutics
|
January 1, 1987
Interpatient and intrapatient variability in vinblastine pharmacokinetics
M J Ratain, N J Vogelzang, J A Sinkule
Cancer Chemotherapy and Pharmacology
|
January 1, 1997
Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital
E Gupta, X Wang, J Ramirez, et al.
Clinical Pharmacology and Therapeutics
|
August 6, 2008
Nonprofit biomedical companies
R M Conti, D O Meltzer, M J Ratain
Page
of 23
Search research articles
Search
Showing results (51-60 of 225) with videos related to
Sort By:
Page
of 23
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 1989
What is the choice of treatment for hairy cell leukemia?
H M Golomb, M J Ratain, J Moormeier
Cancer Research
|
August 1, 1986
Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum(II) in patients with advanced cancer
R L Schilsky, K O'Laughlin, M J Ratain
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 1, 1995
Pushing the envelope: informed consent in phase I trials
C K Daugherty, M J Ratain, M Siegler
Clinical Pharmacology and Therapeutics
|
July 23, 2013
CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality
M J Ratain, Y Nakamura, N J Cox
Cancer Surveys
|
January 1, 1993
Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring
K Kobayashi, D I Jodrell, M J Ratain
Blood
|
June 15, 1990
Duration of response after interferon treatment of hairy cell leukemia
R Mick, M J Ratain, H M Golomb
Clinical Pharmacology and Therapeutics
|
January 13, 2016
The Outlier in All of Us: Why Implementing Pharmacogenomics Could Matter for Everyone
P H O'Donnell, K Danahey, M J Ratain
Clinical Pharmacology and Therapeutics
|
January 1, 1987
Interpatient and intrapatient variability in vinblastine pharmacokinetics
M J Ratain, N J Vogelzang, J A Sinkule
Cancer Chemotherapy and Pharmacology
|
January 1, 1997
Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital
E Gupta, X Wang, J Ramirez, et al.
Clinical Pharmacology and Therapeutics
|
August 6, 2008
Nonprofit biomedical companies
R M Conti, D O Meltzer, M J Ratain
Page
of 23